New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 15, 2021 - The FDA approved Octapharma’s Octagam 10% (immune globulin intravenous [human]), for the treatment of dermatomyositis in adults.
Download PDF
Return to publications
